Abstract
The favorable nuclear properties of rhenium-188 for therapeutic application are described, together with new methods for the preparation of high yield and stable (188)Re radiopharmaceuticals characterized by the presence of the nitride rhenium core in their final chemical structure. (188)Re is readily available from an (188)W/(188)Re generator system and a parallelism between the general synthetic procedures applied for the preparation of nitride technetium-99m and rhenium-188 theranostics radiopharmaceuticals is reported. Although some differences between the chemical characteristics of the two metallic nitrido fragments are highlighted, it is apparent that the same general procedures developed for the labelling of biologically active molecules with technetium-99m can be applied to rhenium-188 with minor modification. The availability of these chemical strategies, that allow the obtainment, in very high yield and in physiological condition, of (188)Re radiopharmaceuticals, gives a new attractive prospective to employ this radionuclide for therapeutic applications.